The continuous emergence of bacterial resistance against existing antibiotics is life threatening to society. Due to the continuous emergence of bacterial resistance and reduced antibiotic approval the society is running out of treatment options against bacterial infections. ‘Soon bacterial infections will be the number one cause of death,’ says Dr. Andreas A. Bastian, CEO and co-founder of the Zernike Campus Groningen based pharmaceutical company AGILeBiotics.
Without acceleration of antibiotic development, death rate will increase by 10-fold by 2050, reaching 250,000 in Europe and 10 million deaths worldwide. The University of Groningen spin-off is developing the next generation antibiotics, which will contribute to the fight against life-threatening bacterial infections; in a quite revolutionary , innovative and for all cost reducing way.
AGILeBiotics employs a new technology, called OxaSelect, that simplifies structural modification of an existing class of antibiotics. This technology has been developed by Dr. Andreas A. Bastian during a joined project between Prof. Andreas Herrmann and Prof. Adriaan Minnaard at the UG in 2011/2012.
Andreas: ‘OxaSelect is a scalable chemical reaction, which will accelerate our in-house antibiotics development against multidrug resistant bacteria of major concern. Moreover, compared to other strategies, OxaSelect reduces the costs during early preclinical studies by 40% and in clinical stages by 20%. Using OxaSelect we have developed a first lead compound, which shows activity against resistant Gram-negative and Gram-positive bacteria. Thanks to OxaSelect the synthesis effort for our antibiotic candidates is reduced by up to 55%.’
In 2012, Andreas Bastian graduated (cum laude) at the Groningen University under supervision of Prof. Andreas Herrmann, cofounder of AGILeBiotics. Awarded with the Rubicon Research Grant, he gained experience in antibiotic development during his postdoc in the group of Prof. Shahriar Mobashery at the University of Notre Dame in the United States. Then, while being employed as Veni Research Fellow at the UG, he decided to launch AGILeBiotics, where he is employing his experience for the development of antibacterials for the pharmaceutical market. AGILeBiotics is developing new antibiotics in close cooperation with Prof Alex Friedrich and Prof. Bhanu Sinha, Genomics for Infection Prevention, UMCG, and Prof. Andreas Herrmann, Polymer Chemistry and Bioengineering, UG. The final goal of AGILeBiotics’ is to out-license an antibiotic candidate in clinical stages.
The office of the company is located at the Innolab for Chemistry building at the Groningen Campus. Innolab is a by Prof Ben Feringa, university of Groningen, initiated incubator for start-ups in the Chemistry that provides lab facilities and business development support. Andreas: ‘This incubator concept is working extremely well for startups and small companies. It allows us to fully focus on the research.’
A success story under way. Andreas: ‘Successful new antibiotic development takes more than 10 years,’ young entrepreneur places his groundbreaking research into perspective. To advance an antibiotic candidate into late clinical studies several rounds of investment are required. After receiving a preseed investment from the RUG Houdstermaatschappij B.V., Hanzepoort B.V, Stichting Ir. G.J. Smid Fonds, AGILeBiotics successfully started the development of novel antibiotics in March 2017.’
Press release ‘ Veni laureate starts spin-off company’ (NWO)
For more information, please contact Andreas A. Bastian
In November the access gates in the University Library City Centre will be tested. If this test proves to be satisfactory, the access gates will be permanently activated.
Digital information technology is permeating society ever deeper. It is now clear that digitalization will radically change virtually every aspect of society, not only in the Netherlands but across the world. That is why 14 Dutch universities, associated...
‘Do you know how often organizations select the wrong manager?’, asks Janka Stoker. ‘Recent research carried out by Gallup shows that this happens in a staggering 82% of cases! These managers were often chosen just because they happened to be very...